Cyclodextrin-poly(anhydride) nanoparticles as new vehicles for oral drug delivery
Authors:
- Socorro EspuelasSocorro Espuelas
- Irene EsparzaIEIrene Esparza
- Patricia CallejaPCPatricia Calleja
- Ivan PeñuelasIPIvan Peñuelas
- Gilles PonchelGPGilles Ponchel
- Juan M IracheJuan M Irache
- 30 March 2011
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 8 (6) , 721-734
Abstract
Introduction: The oral administration of drugs belonging to Class IV of the Biopharmaceutical Classification System (BCS) represents a major challenge. These drugs display poor aqueous solubility and specific permeability characteristics. Most of these compounds are substrates of the P-glycoprotein and/or the cytochrome P450. Among other types of drug, various anti-cancer drugs also suffer from these drawbacks (i.e., paclitaxel), which limits the possibilities for developing oral treatments. Areas covered: This review discusses the factors that influence the bioavailability of drugs when administered by the oral route, as well as the capabilities of cyclodextrins when associated with nanoparticles. In particular, evidence is given regarding the synergistic effect between cyclodextrins and bioadhesive nanoparticles, on the oral delivery of pharmaceuticals. Expert opinion: This article aims to provide an overview of the multiple gains in incorporating cyclodextrins in poly(anhydride) nanoparticles, includin...Keywords
This publication has 88 references indexed in Scilit:
- Considerations when choosing oral chemotherapy: identifying and responding to patient needEuropean Journal of Cancer Care, 2010
- Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World’s Top Oral DrugsThe AAPS Journal, 2009
- Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin deliveryEuropean Journal of Pharmaceutics and Biopharmaceutics, 2009
- Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiersJournal of Controlled Release, 2008
- Gut instincts: CYP3A4 and intestinal drug metabolismJournal of Clinical Investigation, 2007
- Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolismJournal of Clinical Investigation, 2007
- Cyclodextrins and their uses: a reviewProcess Biochemistry, 2004
- Involvement of cholesterol in the inhibitory effect of dimethyl‐β‐cyclodextrin on P‐glycoprotein and MRP2 function in Caco‐2 cellsFEBS Letters, 2003
- Isolation, Purification and Characterization of Cyclomaltooctadecaose (.NU.-Cyclodextrin), Cyclomaltononadecaose (.ZETA.-Cyclodextrin), Cyclomaltoeicosaose (o-Cyclodextrin) and Cyclomaltoheneicosaose (.PI.-Cyclodextrin).Chemical and Pharmaceutical Bulletin, 1998
- Inhibition and Induction of Cytochrome P450 and the Clinical ImplicationsClinical Pharmacokinetics, 1998